v3.26.1
SEGMENT INFORMATION (Notes)
 9 Months Ended
Jul. 31, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
 
Our President and Chief Executive Officer is the chief operating decision maker ("CODM"). The three operating segments were determined based primarily on how the CODM views and evaluates our operations. The CODM uses segment net revenue and income from operations to assess the performance of the segments by reviewing budget to actual variances on a monthly basis. The CODM also uses segment net revenue and income from operations when making decisions about allocating capital and personnel resources predominantly during the annual strategic planning process. The CODM does not evaluate the segments using asset or liability information.
Description of Segments. We are a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.
A description of our three reportable segments is as follows:
Our Life Sciences and Diagnostics Markets segment is comprised of seven areas of activity. We provide active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our liquid chromatography and liquid chromatography mass spectrometry businesses enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Second, our electrophoresis and cell phenotyping business delivers end-to-end workflow solutions (including instruments, reagents, consumables, and software) for nucleic acid quality control and multiparametric cell analysis. These offerings support next-generation sequencing accuracy and enable live-cell imaging, metabolism analysis, and flow cytometry across clinical and life science research applications. Third, our cell imaging and metabolism business provides integrated instruments, reagents, software, and labware for automated imaging, metabolic analysis, plate reading, and dispensing, supporting applications across immunology, oncology, drug discovery, and translational research. Fourth, our Agilent Advanced Therapeutics business (formerly known as our specialty contract development and manufacturing organization ("CDMO") business) provides good manufacturing practice compliant services and manufacturing of synthesized oligonucleotides used as active pharmaceutical ingredients in nucleic acid-based drugs, alongside capabilities in microbial fermentation, bioreagents, highly potent active pharmaceutical ingredients, peptide purification and broader nucleic acid biomanufacturing. Fifth, our pathology solutions business delivers products for cancer diagnostics and anatomic pathology workflows, including immunohistochemistry, in situ hybridization, hematoxylin and eosin, and special staining. The portfolio also includes clinical flow cytometry reagents and bulk antibodies, as well as assay development services for in vitro diagnostics, biotechnology, and pharmaceutical customers. Sixth, we also collaborate with several major pharmaceutical companies to develop new potential tissue pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Finally, our genomics business provides reagents for next-generation sequencing and array workflows, along with solutions that enable clinical labs to identify disease-associated DNA variants and inform cancer therapy.

Our Agilent CrossLab segment provides an extensive services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represents a broad range of offerings designed to serve customer needs across end-markets and applications. Our services portfolio includes repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting and various other custom services to support the customers' laboratory operations. Custom services are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements. Our consumables portfolio is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning we can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries to supplies. Key product categories in consumables include gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and a large selection of laboratory supplies. Software and informatics solutions include software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management. This software facilitates the compliant use of instruments in pharmaceutical quality assurance and quality control environments. The OpenLab laboratory software suite is a scalable, open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. Laboratory automation offers automated sample preparation solutions, including liquid handling, plate management, consumables and scheduling
software. These solutions range from standalone automation platforms to integrated workflow solutions with seamless integration to our instrumentation.

Our Applied Markets segment provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Our gas chromatography and gas chromatography mass spectrometry businesses enable customers to perform a wide variety of testing including measuring volatile and semi-volatile contaminants to assess the safety of our foods, quality of water and consumer products while also enabling testing of fuels and purity of chemicals. Our inductively coupled plasma mass spectrometry, inductively coupled plasma optical emission spectrometry, atomic absorption and microwave plasma-atomic emission spectrometry instruments are vital for our customers to measure metals and elemental signatures in their samples and find uses in the food safety, environmental quality, chemicals manufacture, advanced materials, energy and forensics markets. Our molecular spectroscopy business including the raman, fluorescence and infrared spectroscopy instruments offer both in-field and in-lab testing solutions in a diverse variety of applications including airport security, explosives testing, narcotics, food quality and chemical characterization. Our vacuum business develops cutting edge products and technologies to test vacuum environments and find uses in a diverse variety of industries including semi-conductor, batteries, chemical manufacturing and advanced materials development. Finally, our remarketed instruments business refurbishes and resells certified pre-owned instruments to value-oriented customers who would like Agilent quality and performance at a budget conscious price.

The following tables reflect segment results under our management reporting system after excluding certain unallocated costs as noted in the reconciliations below:
Life Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotal
(in millions)
Three Months Ended July 31, 2026:
Net Revenue$746 $786 $346 $1,878 
Segment Expenses (1)
Cost of products and services332 338 148 
Research and development66 28 24 
Selling, general and administrative172 150 88 
Reportable segment income from operations$176 $270 $86 $532 
Three Months Ended July 31, 2025:
Net Revenue$670 $744 $324 $1,738 
Segment Expenses (1)
Cost of products and services332 334 150 
Research and development61 26 23 
Selling, general and administrative159 136 80 
Reportable segment income from operations$118 $248 $71 $437 
(1) Share-based compensation expense and depreciation expense included in segment expenses are shown below:
Share-Based Compensation ExpenseDepreciation Expense
Three Months Ended July 31,
Three Months Ended July 31,
2026202520262025
(in millions)(in millions)
Life Sciences and Diagnostics Markets$11 $8 $24 $25 
Agilent CrossLab$12 $9 $14 $14 
Applied Markets$5 $4 $6 $6 
Life Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotal
(in millions)
Nine Months Ended July 31, 2026:
Net Revenue$2,157 $2,303 $1,051 $5,511 
Segment Expenses (1)
Cost of products and services1,005 1,016 457 
Research and development195 84 72 
Selling, general and administrative511 451 263 
Reportable segment income from operations$446 $752 $259 $1,457 
Nine Months Ended July 31, 2025:
Net Revenue$1,971 $2,153 $963 $5,087 
Segment Expenses (1)
Cost of products and services946 957 440 
Research and development183 79 69 
Selling, general and administrative478 417 240 
Reportable segment income from operations$364 $700 $214 $1,278 
(1) Share-based compensation expense and depreciation expense included in segment expenses are shown below:
Share-Based Compensation ExpenseDepreciation Expense
Nine Months Ended July 31,
Nine Months Ended July 31,
2026202520262025
(in millions)(in millions)
Life Sciences and Diagnostics Markets$36 $32 $76 $72 
Agilent CrossLab$40 $36 $42 $42 
Applied Markets$18 $17 $19 $18 

The following table reconciles reportable segments' income from operations to Agilent’s total enterprise income before taxes: 
Three Months EndedNine Months Ended
July 31,July 31,
2026202520262025
(in millions)
Total reportable segment income from operations$532 $437 $1,457 $1,278 
Unallocated costs:
Amortization of intangible assets related to business combinations(21)(26)(59)(81)
Acquisition and integration costs(7)(3)(22)(15)
Transformational initiatives(37)(18)(95)(48)
Restructuring and other related costs(15)(17)(43)(74)
Other(8)(13)(42)(24)
Total unallocated costs(88)(77)(261)(242)
Income from operations444 360 1,196 1,036 
Interest income15 16 43 45 
Interest expense(29)(28)(79)(85)
Other income (expense), net14 18 56 (3)
Income before taxes, as reported$444 $366 $1,216 $993 
A portion of the segments' expenses arises from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include finance, tax, treasury, legal, real estate, insurance services, workplace services, human resources, information technology services, corporate development and other corporate infrastructure expenses, costs of centralized research and development and joint sales and marketing costs. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate certain costs to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Unallocated costs consist of asset impairments, amortization of acquisition-related intangible assets, acquisition and integration costs, transformational initiatives expenses, restructuring and other related costs and certain other charges. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers including costs to move manufacturing, site consolidations, legal entity and other business reorganizations, in-sourcing or outsourcing of activities. Included in this category are also expenses associated with the recent transformation and company programs to transform our product lifecycle management system and human resources and financial systems.